Drug Channels

APRIL 16, 2024

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialty pharmacy trends.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Marketing Hospitals 96

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m. d/b/a Drug Channels Institute.

Marketing 97

Marketing Biosimilars Drugs Hospitals 97

Drug Channels

MARCH 28, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights. All rights reserved.

Marketing 98

Marketing Science Therapies Production 98

Drug Channels

MAY 23, 2023

In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. to 1:30 p.m. Click here to learn more and sign up.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

MARCH 8, 2022

The total share of the largest 15 companies decreased slightly compared with their 2020 share, due primarily to below-market growth rates at retail and long-term care pharmacies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. prescription dispensing revenues reached a record $501 billion in 2021.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

JULY 12, 2022

For more on 340B and the specialty market, join me for my upcoming July 29 live video webinar, Specialty Drugs Update: Trends, Controversies, and Outlook. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Read on for details and my commentary below. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Marketing Hospitals Drugs 98

Drug Channels

JUNE 6, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Full salary data below for your enjoyment or sorrow. As expected, the past few years have been highly challenging for retail-employed pharmacists. Expect further declines as the shakeout continues. d/b/a Drug Channels Institute. This Feed is for personal non-commercial use only.

Pharmacy 98

Pharmacy Hospitals Marketing Drugs 98

Drug Channels

MARCH 12, 2024

prescription dispensing revenues reached $621 billion in 2023, driven by accelerating GLP-1 prescriptions and an expanding post-pandemic market. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. It’s the 15th edition of our popular and comprehensive examination of the entire U.S.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

MAY 9, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. FYI, Managed Healthcare Executive (accurately) described my presentation as " mixing jokes with data and PowerPoint slides." Yes, that sounds about right. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Marketing Pharmacy Drugs 98

Drug Channels

MARCH 8, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Find out at my upcoming live video webinar, Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook , on March 31, 2023, from 12:00 p.m. to 1:30 p.m. Click here to learn more and sign up. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Specialty Pharmacies Marketing Drugs 98

Drug Channels

OCTOBER 28, 2021

Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. To learn more about technology and access to specialty medications, read the CoverMyMeds Medication Access Report: Complex Care & Specialty Edition. Read on for Megan’s insights. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Marketing 75

Marketing Drugs 75

Drug Channels

SEPTEMBER 24, 2021

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Click here to see the original post and comments from June 2021. d/b/a Drug Channels Institute.

Hospitals 69

Hospitals Marketing Drugs Pharmacy 69

Drug Channels

APRIL 4, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

APRIL 18, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. While this is a longer-than usual post, I can still only barely scratch the surface of the many far-reaching effects of this legislation. As always, I encourage you to share your own thoughts in the comments below or on social media. d/b/a Drug Channels Institute.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

JUNE 21, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. As you will see below, Dr. Gottlieb was right.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

JUNE 20, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. While this is a longer-than usual post, I can still only barely scratch the surface of the many far-reaching effects of this legislation. As always, I encourage you to share your own thoughts in the comments below or on social media. d/b/a Drug Channels Institute.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

MAY 9, 2024

To learn more about navigating the complexities of market access, contact MMIT and its sister company, The Dedham Group. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. They discuss five ways manufacturers can prevent these barriers from affecting patients. Read on for their insights.

Therapies 98

Therapies Marketing Drugs 98

Drug Channels

DECEMBER 17, 2020

The biosimilar market is finally beginning to fulfill its promise. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. HHS relied in part on a highly misleading ASPE study of 2018 data.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

MAY 2, 2024

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Chris explains how the Inflation Reduction Act of 2022 (IRA) will impact hub, patient assistance programs (PAP), and affordability programs.

Marketing 98

Marketing Drugs 98

Drug Channels

APRIL 5, 2022

The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

JULY 25, 2022

The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

AUGUST 5, 2022

To test the efficacy of your market access digital strategy against industry best practices, take the OptimizeRx Market Access Strategy Quiz. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Read on for Karina’s insights. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Therapies Marketing Drugs 98

Drug Channels

APRIL 7, 2023

Today’s guest post comes from Heather Roulston, Market Research Manager at MMIT. For additional market insights, click here to learn about MMIT’s Biologics & Injectables Index. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Heather also shares data on payers’ site-of-care management strategies.

Marketing 98

Marketing Production Drugs Research 98

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read on for Steve’s insights. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharma Companies Marketing Drugs 98

Drug Channels

JULY 11, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Manufacturers’ contract pharmacy policy changes have slowed profits at pharmacies and PBMs, while triggering change in hospitals’ pharmacy strategies. Read on for my latest effort to pierce these little webs of 340B opacity. d/b/a Drug Channels Institute.

Pharmacy 74

Pharmacy Marketing Hospitals Drugs 74

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. Read on for Saket’s insights.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

Drug Channels

JANUARY 4, 2024

HMP is a leading omnichannel healthcare education, events, and market insights company. Here’s the press release: HMP Global Expands Market Reach with Strategic Acquisition of Drug Channels Institute; Launches Market Intelligence Unit Paula and I will continue to lead DCI as part of HMP. It’s a great fit for DCI.

Drugs 97

Drugs Marketing 97

Drug Channels

JUNE 12, 2024

The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D.,

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Marketing 52

Drug Channels

MARCH 4, 2025

Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars. All rights reserved.

Pharmacy 94

Pharmacy Specialty Pharmacies Marketing Drugs 94

Drug Channels

MARCH 11, 2022

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Stacey analyzes trends in patient support services and reimbursement hubs. Click here to schedule your meeting. Read on for Stacey’s insights.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Therapies Marketing 97

Drug Channels

DECEMBER 9, 2022

Today’s guest post comes from Leslie Small, Managing Editor, and Jinghong Chen, Reporter, at Health Plan Weekly , published by AIS Health, the journalism division of Managed Markets Insight & Technology, LLC. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Read on for Leslie’s and Jinghong’s insights.

Packaging 98

Packaging Marketing Drugs 98

Drug Channels

JANUARY 21, 2022

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Chris discusses how COVID-19 is impacting stakeholders across the healthcare system, including patients, providers, pharmacies, and manufacturers.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

MARCH 17, 2023

Today’s guest post comes from Rhiannon Naslund, Chief Marketing Officer at Kalderos. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Rhiannon discusses the growing collaboration between manufacturers and covered entities regarding 340B discount claims. Read on for Rhiannon’s insights. d/b/a Drug Channels Institute.

Marketing 98

Marketing Drugs 98

Drug Channels

NOVEMBER 19, 2021

She argues, however, that these pathways often shut manufacturers out of the market. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access. Read on for Carolyn’s insights.

Treatment 98

Treatment Marketing Drugs 98

Drug Channels

AUGUST 25, 2023

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Chris discusses how such copay adjustment programs as accumulators and maximizers impact patients. Read on for Chris’ insights. d/b/a Drug Channels Institute.

Marketing 98

Marketing Drugs 98

Drug Channels

FEBRUARY 2, 2024

Today’s guest post comes from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Divya shares highlights from GoodRx’s new research report: The GoodRx Effect: How GoodRx Improves the Economics of Healthcare. Read on for Divya’s insights.

Therapies 98

Therapies Marketing Research Drugs 98